Factor XI

Ask MedXY AI

Latest news

Tag

Hematology-OncologycenvacibartFactor XI

Innovative Anticoagulation: Targeting Factor XI with Amrecibart and Cenvacibart for Safer Thrombosis Prevention

By MedXY|Oct 17, 2026

Factor XI-targeted antibodies, amrecibart and cenvacibart, offer promising anticoagulation by selectively inhibiting intrinsic coagulation pathways, potentially reducing thrombosis without increasing bleeding risk.

Hematology-OncologyanticoagulationFactor XI

Factor XI Inhibition Redefined: Catalytic Domain Blockade Emerges as a Superior Strategy for VTE Prevention

By MedXY|Jan 13, 2026

The ROXI-VTE trials demonstrate that inhibiting the Factor XI catalytic domain significantly reduces postoperative VTE compared to enoxaparin. While blocking Factor XIIa-mediated activation showed promise, it failed to meet superiority, hig